Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M807Revenue $M83.2Net Margin (%)0Z-Score0
Enterprise Value $M807EPS $0Operating Margin %0F-Score0
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yN
Price/Book010-y EBITDA Growth Rate %0Quick Ratio0Cash flow > EarningsN
Price/Sales05-y EBITDA Growth Rate %0Current Ratio0Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)0Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M0ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with ASTX

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
ASTXMario Gabelli 2013-12-31 Sold Out -0.01%$8.48 - $8.63
$ 8.50%Sold Out0
ASTXMario Gabelli 2013-09-30 Buy 0.01%$4.43 - $8.86
$ 8.534%New holding, 157573 sh.157,573
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ASTX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!

ASTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MANUSO JAMES S JCEO 2013-05-14Sell29,500$5.8445.55 view
CASAMENTO CHARLES JDirector 2013-05-03Sell71,000$5.8744.8 view
MANUSO JAMES S JCEO 2013-05-02Sell38,000$5.8744.8 view
Jhoti HarrenPresident 2013-03-15Sell10,000$4.25100 view
CASAMENTO CHARLES JDirector 2013-03-13Sell14,000$4.2799.06 view
MANUSO JAMES S JCEO 2013-03-08Sell40,000$4.493.18 view

Press Releases about ASTX :

    Quarterly/Annual Reports about ASTX:

    News about astx:

    Articles On GuruFocus.com
    Recommended by fool. Sep 16 2012 

    More From Other Websites
    Astex Pharmaceuticals Presents Final Results of Phase 2 Study of SGI-110 in Treatment Naïve Elderly... Jun 16 2014
    ASTEX PHARMACEUTICALS, INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Oct 11 2013
    Otsuka Pharmaceutical Completes Acquisition of Astex Pharmaceuticals Oct 11 2013
    Sarissa Capital Highlights Advancement Of Astex Pipeline Compound Oct 09 2013
    Sarissa Capital Urges All Shareholders Of Astex Pharmaceuticals To Not Tender Their Shares At... Oct 08 2013
    US STOCKS-Futures fall on uncertainty over when impasse will end Oct 03 2013
    Is This the Top for Astex Pharmaceuticals, Inc. (ASTX) Oct 03 2013
    Astex Pharma shareholder opposes $886 mln bid by Otsuka Oct 02 2013
    Astex Shareholder Sarissa Says It Won’t Tender Shares Oct 02 2013
    Hedge fund Sarissa opposes Astex sale to Otsuka Oct 02 2013
    Sarissa Capital Issues Open Letter Regarding Astex Pharmaceuticals Oct 02 2013
    Top Biotech Stock Picks for Q4 2013: An Interview with the Senior Analyst at Oppenheimer & Company Sep 13 2013
    Wall Street Transcript Interview with James S.J. Manuso, the Chairman and CEO of Astex... Sep 13 2013
    Astex Sued by Shareholder Over $886 Million Otsuka Bid Sep 13 2013
    Sarissa’s Denner Targets Astex Amid Ire Over Otsuka Deal Sep 11 2013
    Astex Pharmaceuticals, Inc. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation into... Sep 09 2013
    Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Astex Pharmaceuticals, Inc.... Sep 09 2013

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    Email Hide